Authors
Latest:
Future Perspectives and Unmet Needs in Multiple MyelomaThe expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
Latest:
Luveltamab Tazevibulin Elicits Response in Platinum-Resistant Ovarian Cancer, Low/Medium FRα ExpressionThe REFRαME-O1 trial improved response in patients with FRα–positive platinum-resistant ovarian cancer, including those with low to medium expression when given luveltamab tazevibulin.
Latest:
Expert Insight and Future Perspectives for Follicular LymphomaPanelists close the discussion by offering insights and future perspectives on the treatment landscape for follicular lymphoma.
Latest:
Current Treatment Paradigm: Evolution of First-Line Therapy for ES-SCLCPanelists discuss how the addition of immune checkpoint inhibitors to first-line chemotherapy has transformed the treatment of extensive-stage small cell lung cancer, improving survival while highlighting ongoing challenges in managing relapse and the need for continued research into novel therapies.
Latest:
Catherin Watson, MD, Assesses the Future of Genetic Testing in Ovarian CancerAt SGO 2022, Catherine Watson, MD, spoke about how to encourage patients with ovarian cancer to seek genetic testing.
Latest:
A Rare Case of Glioblastoma With Extensive Liver MetastasesGhulam Gous, MD, and colleagues report a case of glioblastoma with extensive liver metastases along with a review of previous reports of liver metastasis from glioblastomas and the possible mechanisms of metastasis.
Latest:
Improving Outcomes in Non-Small Cell Lung Cancer: Future Directions in CareBest treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.
Latest:
Data Show Underutilization of Appendectomy in Appendix Cancer PopulationA lack of guidelines, a loss of follow-up, and out-of-state procedures are all potential reasons for 26% of patients undergoing appendectomy.
Latest:
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical TrialsThese data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Latest:
Future Perspectives: Treating Multiple Myeloma With Novel RegimensAn overview of what’s next, in terms of the use of various frontline treatment regimens, that include novel agents to manage patients with newly diagnosed multiple myeloma.
Latest:
KRAS+ NSCLC: Treatment Management StrategiesThis video segment discusses strategies for patient education and preparation for second-line treatment with RAS GTPase inhibitors, as well as therapeutic options to consider if a patient progresses on adagrasib.
Latest:
Exploring the Future of ctDNA and Novel Treatment StrategiesPanelists offer concluding perspectives on the future role of circulating tumor DNA in colorectal cancer management.
Latest:
Kim A. Reiss Binder, MD, Reviews PARP Plus Immunotherapy in Platinum-Sensitive Advanced Pancreatic AdenocarcinomaKim A. Reiss Binder, MD, spoke about the use of niraparib plus either nivolumab or ipilimumab for patients with platinum-sensitive advanced pancreatic adenocarcinoma.
Latest:
Codon 12 Mutations May Signal Benefit With RMC-6236 in PDACThe mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Unmet Needs and Future Perspectives in Newly-Diagnosed and Relapsed Multiple MyelomaClosing out their discussion, the panel shares remaining unmet needs in the treatment of newly-diagnosed and relapsed multiple myeloma.
Latest:
Redefining the Treatment Paradigm in Low Grade Serous Ovarian CancerLow grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Latest:
CAR-NKT cells: More of a Goldilocks or a Kangaroo?The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.
